The Importance of Equity in Prostate Cancer Clinical Trials
Dr. Zachary Klaassen and Dr. Samuel Washington discuss the importance of diversity and equitable representation in prostate cancer clinical trials, highlighting barriers that have historically limited participation among underrepresented populations. They explain how inclusive clinical trials can improve research outcomes, expand access to care, and help ensure treatments benefit all patients.
Dr. Zachary Klaassen:
Hi, my name is Zach Klaassen, urological oncologist in Augusta, Georgia, and I'm delighted to be joined on Prostate Cancer Patient Voices by Dr. Sam Washington, who is a urologic oncologist at UCF in San Francisco. Today, we'll be discussing clinical equity and the importance for clinical trials. Sam, always great catching up with you. Thanks for joining us.
Dr. Samuel Washington:
Yeah, thanks for having me. Happy to chat.
Dr. Zachary Klaassen:
So from a patient level, just tell us what exactly a clinical trial is and why we do them in medicine.
Dr. Samuel Washington:
Yeah, so the key thing that we're trying to do with clinical trials, again, a study to answer a question: does a drug work better? Does an imaging test work better? Does some intervention work better than another? Comparing that in a structured way is a clinical trial. There's different ways to structure that trial, but the key thing is that it helps us answer questions by controlling for a lot of things that we can't directly measure. Give us a cleaner answer, if you will.
Dr. Zachary Klaassen:
That's a great explanation. The topic today is inequities in clinical trials, and one of those has been underrepresented minorities have often been excluded or not included or not discussed about a clinical trial. What's sort of the background or the history behind some of those reasons?
Dr. Samuel Washington:
I think there's a lot that goes into the history, and it's important of how access to clinical trials, access to medical care, access to new technologies, and new drugs has always been different for different populations. There's a lot of inputs going into that. Historically, when it comes to opportunities for new clinical trials, it's been all the things you mentioned.
Are they being discussed? Are patients from minoritized populations able to get into places that are doing clinical trials? And then for the clinical trials themselves, are they structured in a way to allow people to participate, or are there too many administrative or logistical hurdles that prevent everyone from getting involved who may be eligible?
Dr. Zachary Klaassen:
Right. And I think when you look at a trial population, it should be representative of the patients we're treating. Just go into why that matters to have adequate representation of minorities in these trials.
Dr. Samuel Washington:
Well, I think in general, our goal is to understand, okay, does this solution work for everyone? Does it work for the entire population? Now, if you exclude portions of the population, you have no idea how generalizable, how this applies to everyone else. Having that representation upfront helps us understand will this drug or imaging study work overall, and then will it work for every population the same way.
Dr. Zachary Klaassen:
There's been a lot of focus around increasing underrepresented minority populations in clinical trials. Maybe just walk through some of the stuff the FDA, the NCI, even industry partners have over the last decade or tried to increase that population in clinical trials.
Dr. Samuel Washington:
Well, I think the key thing that happened was recognition that there needs to be more intentional moves towards that. Some of that has been programmatic and structural, decreasing the requirements to get involved or participation in clinical trials, increasing requirements that the representativeness of your study looks like your population.
That's pushed cancer centers and other institutions to understand what their population's demographics look like, to mirror those in studies. There's also been other incentives in terms of support, financial, infrastructure, logistics to get more people involved in these studies. Again, going back to understanding how well this comparison works across all the people that we treat.
Dr. Zachary Klaassen:
That's great. Hopefully there's somebody out there listening to us that's maybe thinking about a trial. Why should a patient go in a clinical trial? What's the, I guess, benefit to them or to the greater population? Maybe just break down why you talk to patients about them and why they should think about it.
Dr. Samuel Washington:
Yeah. Obviously biased, getting involved with the science and moving the field forward is always exciting.
Dr. Zachary Klaassen:
From our standpoint, for sure.
Dr. Samuel Washington:
From our standpoint, from an academic standpoint. For a patient, though, getting involved means more oversight, actually. The concern oftentimes, which is a real concern, is: how is your care going to differ from what you should be getting and what you actually get? Clinical trial brings so much investment, and attention, and structure.
It ensures that you're getting very good care, very structured, monitored care, not only just from the structure of the study itself, but everyone involved is incentivized to make sure that that trial runs smoothly and everyone gets what they should. So there's that hidden nested benefit in addition to whatever benefit you may get from the intervention or the drug, the question being asked.
Dr. Zachary Klaassen:
There's a lot of eyeballs looking at you and your chart, and that's often very helpful for patients in today's medical system, which can be difficult to navigate and get people on the phone, et cetera. That doesn't happen in a clinical trial. Last question is, what are some reliable places patients could look for clinical trials? I know prostatecancerpatientvoices.com has some, but in your opinion, where do you direct patients for looking for trials?
Dr. Samuel Washington:
Yeah, I mean, the easiest thing often is to ask your provider, so the person you're seeing. Clinicaltrial.gov is a site that us academicians use, but can often be difficult to navigate. There are other websites, and I think we'll be providing some as well that can be very good sources. The question is often, are you eligible for the clinical trial? And then where may you be able to participate? Which site is participating in the trial? So answering both of those is often a discussion.
Dr. Zachary Klaassen:
Awesome. Sam, super helpful. I think we come together to try to get all patients in clinical trials, specifically underrepresented minorities are really important for understanding, as you mentioned, the generalizability of this, getting them in, getting them access to care. Thanks so much for joining us.
Dr. Samuel Washington:
Thanks for having me.
